The GLP-1 receptor agonists exendin-4 and liraglutide alleviate oxidative stress and cognitive and micturition deficits induced by middle cerebral artery occlusion in diabetic mice

BMC Neuroscience

Volumn 17, Issue 1, 2016, Pages

  Li, Ping Chia ^a   Liu, Li Fen ^a   Jou, Ming Jia ^a   Wang, Hao Kuang ^a  

^a I SHOU UNIVERSITY   (Taiwan)

Author keywords

Cerebral microcirculation; GLP 1 agonist; Middle cerebral artery occlusion; Oxidative stress; Pelvic nerve; Voiding function

Indexed keywords

CASPASE 3; ENDOTHELIAL NITRIC OXIDE SYNTHASE; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; LIRAGLUTIDE; MANGANESE SUPEROXIDE DISMUTASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN BAX; PROTEIN BCL 2; PROTEIN KINASE B; REACTIVE OXYGEN METABOLITE; ANTIDIABETIC AGENT; GLP1R PROTEIN, MOUSE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; NOOTROPIC AGENT; PEPTIDE; PROTECTIVE AGENT; VENOM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; BRAIN BLOOD FLOW; COGNITIVE DEFECT; CONTROLLED STUDY; DIABETES MELLITUS; MALE; MICTURITION DISORDER; MIDDLE CEREBRAL ARTERY OCCLUSION; MOUSE; NONHUMAN; OXIDATIVE STRESS; PARASYMPATHETIC NERVE; PELVIC NERVE; PROTEIN EXPRESSION; AGONISTS; ANIMAL; BRAIN CIRCULATION; COGNITION DISORDERS; COMPLICATION; DIABETES MELLITUS, EXPERIMENTAL; DRUG EFFECTS; INFARCTION, MIDDLE CEREBRAL ARTERY; METABOLISM; MOVEMENT DISORDERS; PATHOPHYSIOLOGY; PHYSIOLOGY; URINATION DISORDERS;

ANIMALS; CEREBROVASCULAR CIRCULATION; COGNITION DISORDERS; DIABETES MELLITUS, EXPERIMENTAL; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; HYPOGLYCEMIC AGENTS; INFARCTION, MIDDLE CEREBRAL ARTERY; LIRAGLUTIDE; MALE; MICE; MOVEMENT DISORDERS; NOOTROPIC AGENTS; OXIDATIVE STRESS; PEPTIDES; PROTECTIVE AGENTS; URINATION DISORDERS; VENOMS;

EID: 84973901403     PISSN: None     EISSN: 14712202     Source Type: Journal    
DOI: 10.1186/s12868-016-0272-9     Document Type: Article

References (50)

1. Jeerakathil T, et al. Short-term risk for stroke is doubled in persons with newly treated type 2 diabetes compared with persons without diabetes: a population-based cohort study. Stroke. 2007;38(6):1739-43.
2. Laing SP, et al. Mortality from cerebrovascular disease in a cohort of 23000 patients with insulin-treated diabetes. Stroke. 2003;34(2):418-21.
3. Chien CT, et al. Exendin-4-loaded PLGA microspheres relieve cerebral ischemia/reperfusion injury and neurologic deficits through long-lasting bioactivity-mediated phosphorylated Akt/eNOS signaling in rats. J Cereb Blood Flow Metab. 2015;35(11):1790-803.
4. Ceriello A, et al. Hyperglycemia-induced circulating ICAM-1 increase in diabetes mellitus: the possible role of oxidative stress. Horm Metab Res. 1998;30(3):146-9.
5. Cominacini L, et al. E-selectin plasma concentration is influenced by glycaemic control in NIDDM patients: possible role of oxidative stress. Diabetologia. 1997;40(5):584-9.
6. Esposito K, et al. Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: role of oxidative stress. Circulation. 2002;106(16):2067-72.
7. Kamada H, et al. Influence of hyperglycemia on oxidative stress and matrix metalloproteinase-9 activation after focal cerebral ischemia/reperfusion in rats: relation to blood-brain barrier dysfunction. Stroke. 2007;38(3):1044-9.
8. Davidson JA, Parkin CG. Is hyperglycemia a causal factor in cardiovascular disease? Does proving this relationship really matter? Yes. Diabetes Care. 2009;32(Suppl 2):S331-3.
9. Khatri JJ, et al. Vascular oxidant stress enhances progression and angiogenesis of experimental atheroma. Circulation. 2004;109(4):520-5.
10. von Harsdorf R, Li PF, Dietz R. Signaling pathways in reactive oxygen species-induced cardiomyocyte apoptosis. Circulation. 1999;99(22):2934-41.
11. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature. 2001;414(6865):813-20.
12. Khan Z, et al. Analysis of voiding disorders in patients with cerebrovascular accidents. Urology. 1990;35(3):265-70.
13. Kataoka K, et al. Cholinergic deafferentation after focal cerebral infarct in rats. Stroke. 1991;22(10):1291-6.
14. Yotsuyanagi S, Narimoto K, Namiki M. Mild brain ischemia produces bladder hyperactivity without brain damage in rats. Urol Int. 2006;77(1):57-63.
15. Nakai M, et al. Acetylcholinesterase inhibitor acting on the brain improves detrusor overactivity caused by cerebral infarction in rats. Neuroscience. 2006;142(2):475-80.
16. Drucker DJ. Minireview: the glucagon-like peptides. Endocrinology. 2001;142(2):521-7.
17. Doyle ME, Egan JM. Glucagon-like peptide-1. Recent Prog Horm Res. 2001;56:377-99.
18. Stoffers DA, et al. Insulinotropic glucagon-like peptide 1 agonists stimulate expression of homeodomain protein IDX-1 and increase islet size in mouse pancreas. Diabetes. 2000;49(5):741-8.
19. Zhou J, et al. Glucagon-like peptide 1 and exendin-4 convert pancreatic AR42J cells into glucagon- and insulin-producing cells. Diabetes. 1999;48(12):2358-66.
20. Chien CT, et al. Glucagon-like peptide-1 receptor agonist activation ameliorates venous thrombosis-induced arteriovenous fistula failure in chronic kidney disease. Thromb Haemost. 2014;112(5):1051-64.
21. Grieve DJ, Cassidy RS, Green BD. Emerging cardiovascular actions of the incretin hormone glucagon-like peptide-1: potential therapeutic benefits beyond glycaemic control? Br J Pharmacol. 2009;157(8):1340-51.
22. Goke R, et al. Distribution of GLP-1 binding sites in the rat brain: evidence that exendin-4 is a ligand of brain GLP-1 binding sites. Eur J Neurosci. 1995;7(11):2294-300.
23. Hamilton A, Holscher C. Receptors for the incretin glucagon-like peptide-1 are expressed on neurons in the central nervous system. NeuroReport. 2009;20(13):1161-6.
24. Perry T, et al. Protection and reversal of excitotoxic neuronal damage by glucagon-like peptide-1 and exendin-4. J Pharmacol Exp Ther. 2002;302(3):881-8.
25. Hirata Y, et al. Exendin-4, a glucagon-like peptide-1 receptor agonist, attenuates neointimal hyperplasia after vascular injury. Eur J Pharmacol. 2013;699(1-3):106-11.
26. Wei Q, Sun YQ, Zhang J. Exendin-4, a glucagon-like peptide-1 receptor agonist, inhibits cell apoptosis induced by lipotoxicity in pancreatic beta-cell line. Peptides. 2012;37(1):18-24.
27. Ke S, et al. Exendin-4 ameliorates high glucose- and TNF-alpha-induced vascular endothelial cell damage by inhibiting p38 MAPK and NF-kappaB p65 translocation. Nan Fang Yi Ke Da Xue Xue Bao. 2012;32(8):1182-5.
28. Hendarto H, et al. GLP-1 analog liraglutide protects against oxidative stress and albuminuria in streptozotocin-induced diabetic rats via protein kinase A-mediated inhibition of renal NAD(P)H oxidases. Metabolism. 2012;61(10):1422-34.
29. Kudo M, et al. IL-17A produced by alpha beta T cells drives airway hyper-responsiveness in mice and enhances mouse and human airway smooth muscle contraction. Nat Med. 2012;18(4):547-54.
30. Bertilsson G, et al. Peptide hormone exendin-4 stimulates subventricular zone neurogenesis in the adult rodent brain and induces recovery in an animal model of Parkinson's disease. J Neurosci Res. 2008;86(2):326-38.
31. Harkavyi A, et al. Glucagon-like peptide 1 receptor stimulation reverses key deficits in distinct rodent models of Parkinson's disease. J Neuroinflammation. 2008;5:19.
32. Kastin AJ, Akerstrom V, Pan W. Interactions of glucagon-like peptide-1 (GLP-1) with the blood-brain barrier. J Mol Neurosci. 2002;18(1-2):7-14.
33. Kastin AJ, Pan W. Peptide transport across the blood-brain barrier. Prog Drug Res. 2003;61(14674609):79-7100.
34. Teramoto S, et al. Exendin-4, a glucagon-like peptide-1 receptor agonist, provides neuroprotection in mice transient focal cerebral ischemia. J Cereb Blood Flow Metab. 2011;31(8):1696-705.
35. Briyal S, Shah S, Gulati A. Neuroprotective and anti-apoptotic effects of liraglutide in the rat brain following focal cerebral ischemia. Neuroscience. 2014;281c:269-81.
36. Darsalia V, et al. Glucagon-like peptide-1 receptor activation reduces ischaemic brain damage following stroke in Type 2 diabetic rats. Clin Sci (Lond). 2012;122(10):473-83.
37. Love S. Oxidative stress in brain ischemia. Brain Pathol. 1999;9(1):119-31.
38. Hui L, et al. The neuroprotection of insulin on ischemic brain injury in rat hippocampus through negative regulation of JNK signaling pathway by PI3K/Akt activation. Brain Res. 2005;1052(1):1-9.
39. Rizk NN, Rafols JA, Dunbar JC. Cerebral ischemia-induced apoptosis and necrosis in normal and diabetic rats: effects of insulin and C-peptide. Brain Res. 2006;1096(1):204-12.
40. Orland MJ, Permutt MA. Genetic susceptibility to diabetes in inbred strains of mice: measurements of proinsulin mRNA and response to dexamethasone. Diabetologia. 1987;30(12):934-9.
41. Han L, et al. Exendin-4 directly improves endothelial dysfunction in isolated aortas from obese rats through the cAMP or AMPK-eNOS pathways. Diabetes Res Clin Pract. 2012;97(3):453-60.
42. Meller R, et al. CREB-mediated Bcl-2 protein expression after ischemic preconditioning. J Cereb Blood Flow Metab. 2005;25(2):234-46.
43. Hockenbery DM, et al. Bcl-2 functions in an antioxidant pathway to prevent apoptosis. Cell. 1993;75(2):241-51.
44. Roviezzo F, et al. Protective role of PI3-kinase-Akt-eNOS signalling pathway in intestinal injury associated with splanchnic artery occlusion shock. Br J Pharmacol. 2007;151(3):377-83.
45. Fu D, et al. Permanent occlusion of the middle cerebral artery upregulates expression of cytokines and neuronal nitric oxide synthase in the spinal cord and urinary bladder in the adult rat. Neuroscience. 2004;125(4):819-31.
46. Zeynalov E, et al. Neuroprotective effect of selective kappa opioid receptor agonist is gender specific and linked to reduced neuronal nitric oxide. J Cereb Blood Flow Metab. 2006;26(3):414-20.
47. Weiss S, et al. Network analysis of rat spatial cognition: behaviorally-established symmetry in a physically asymmetrical environment. PLoS One. 2012;7(7):e40760.
48. Chien CT, et al. Reduction in renal haemodynamics by exaggerated vesicovascular reflex in rats with acute urinary retention. J Physiol. 2000;526(Pt 2):397-408.
49. Chien CT, et al. Inhibitory effect of botulinum toxin type A on the NANC system in rat respiratory models of neurogenic inflammation. Arch Biochem Biophys. 2012;524(2):106-13.
50. Li PC, et al. Repetitive progressive thermal preconditioning hinders thrombosis by reinforcing phosphatidylinositol 3-kinase/Akt-dependent heat-shock protein/endothelial nitric oxide synthase signaling. J Vasc Surg. 2012;56(1):159-70.